{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:22:19Z","timestamp":1787314939684,"version":"build-2736575974"},"reference-count":79,"publisher":"Bentham Science Publishers Ltd.","issue":"43","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Antimicrobial resistance is an aggravating global issue therefore it has been under extensive research\nin an attempt to reduce the number of antibiotics that are constantly reported as obsolete jeopardizing the lives\nof millions worldwide. Thiazoles possess a reputation as one of the most diverse biologically active nuclei, and\nphenylthiazoles are no less exceptional with an assorted array of biological activities such as anthelmintic, insecticidal, antimicrobial, antibacterial, and antifungal activity [1]. Recently phenyl thiazoles came under the\nspotlight as a scaffold having strong potential as an anti-MRSA lead compound. It is a prominent pharmacophore in designing and synthesizing new compounds with antibacterial activity against multidrug-resistant bacteria such as MRSA, which is categorized as a serious threat pathogen, that exhibited concomitant resistance to\nmost of the first-line antibiotics. MRSA has been associated with soft tissue and skin infections resulting in\nhigh death rates, rapid dissemination, and loss of millions of dollars of additional health care costs [2]. In this\nbrief review, we have focused on the advances of phenylthiazole derivatives as potential anti-MRSA from 2014\nto 2021. The review encompasses the effect on biological activity due to combining this molecule with various\nsynthetic pharmacophores. The physicochemical aspects were correlated with the pharmacokinetic properties\nof the reviewed compounds to reach a structure-activity relationship profile. A summary of antibacterial activity\nof phenylthiazole derivatives against MRSA was added in a tabular form (Table 1). Lead optimization of phenyl thiazole derivatives has additionally been outlined where the lipophilicity of the compounds was balanced\nwith the metabolic stability and oral solubility to aid the researchers in medicinal chemistry, design, and synthesizing effective anti-MRSA phenylthiazoles in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1381612829666221124112006","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:00:17Z","timestamp":1669338017000},"page":"3469-3477","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Anti-MRSA Activity of Phenylthiazoles: A Comprehensive Review"],"prefix":"10.2174","volume":"28","author":[{"given":"Asmaa E.","family":"Kassab","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inas G.","family":"Shahin","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts, Giza 11787, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled O.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza T.","family":"Taher","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt;"},{"name":"Department of\nPharmaceutical Organic Chemistry, College of Pharmacy, October 6 University, 6-October, Giza, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman S.","family":"Mayhoub","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical\nOrganic Chemistry, College of Pharmacy, Al-Azhar University, Cairo 11884, Egypt"},{"name":"University of Science and Technology,\nNanoscience Program, Zewail City of Science and Technology, October Gardens, 6th October, Giza 12578, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Frieden T.","year":"2019","unstructured":"Frieden T.; Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention 2019","journal-title":"Centers for Disease Control and Prevention"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/0974-777X.157245","volume":"7","author":"Kaur D.","year":"2015","unstructured":"Kaur D.; Chate S.; Study of antibiotic resistance pattern in methicillin resistant Staphylococcus aureus with special reference to newer antibiotic. J Glob Infect Dis 2015,7(2),78-84","journal-title":"J Glob Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/CE.S33430","volume":"7","author":"Watkins R.","year":"2012","unstructured":"Watkins R.; Lemonovich T.L.; File T.; An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): Place in therapy. Core Evid 2012,7,131-143","journal-title":"Core Evid"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.17311\/sciintl.2013.253.260","volume":"1","author":"Gupta V.","year":"2013","unstructured":"Gupta V.; Kant V.; A review on biological activity of imidazole and thiazole moieties and their derivatives. Sci Int 2013,1(7),253-260","journal-title":"Sci Int"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1021\/jm401905m","volume":"57","author":"Mohammad H.","year":"2014","unstructured":"Mohammad H.; Mayhoub A.S.; Ghafoor A.; Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus. J Med Chem 2014,57(4),1609-1615","journal-title":"J Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/(SICI)1521-4184(199910)332:10<343:AID-ARDP343>3.0.CO;2-0","volume":"332","author":"Ergen&#xE7; N.","year":"1999","unstructured":"Ergen&#xE7; N.; &#xC7;apan G.; G&#xFC;nay N.S.; Synthesis and hypnotic activity of new 4-thiazolidinone and 2-thioxo-4,5-imidazolidine-dione derivatives. Arch Pharm 1999,332(10),343-347","journal-title":"Arch Pharm"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/jps.2600831013","volume":"83","author":"Hays S.J.","year":"1994","unstructured":"Hays S.J.; Rice M.J.; Ortwine D.F.; Substituted 2-benzothiazol-amines as sodium flux inhibitors: Quantitative structure-activity relationships and anticonvulsant activity. J Pharm Sci 1994,83(10),1425-1432","journal-title":"J Pharm Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejmech.2008.02.007","volume":"44","author":"Azam F.","year":"2009","unstructured":"Azam F.; Alkskas I.A.; Khokra S.L.; Prakash O.; Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants. Eur J Med Chem 2009,44(1),203-211","journal-title":"Eur J Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.ejmech.2009.12.062","volume":"45","author":"Siddiqui N.","year":"2010","unstructured":"Siddiqui N.; Ahsan W.; Triazole incorporated thiazoles as a new class of anticonvulsants: Design, synthesis and in vivo screening. Eur J Med Chem 2010,45(4),1536-1543","journal-title":"Eur J Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0960-894X(02)00930-7","volume":"13","author":"Hutchinson I.","year":"2003","unstructured":"Hutchinson I.; Bradshaw T.D.; Matthews C.S.; Stevens M.F.G.; Westwell A.D.; Antitumour benzothiazoles. Part 20: 3\u2032-Cyano and 3\u2032-Alkynyl-Substituted 2-(4\u2032-Aminophenyl)benzothiazoles as new potent and selective analogues. Bioorg Med Chem Lett 2003,13(3),471-474","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(SICI)1521-4184(19994)332:4<137:AID-ARDP137>3.0.CO;2-0","volume":"332","author":"El-Subbagh H.I.","year":"1999","unstructured":"El-Subbagh H.I.; Abadi A.H.; Lehmann J.; 2,4-Disubstituted thiazoles, Part III. Synthesis and antitumor activity of ethyl 2-substituted-aminothiazole-4-carboxylate analogs. Arch Pharm 1999,332(4),137-142","journal-title":"Arch Pharm"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/15533170600651405","volume":"36","author":"Shao L.","year":"2006","unstructured":"Shao L.; Zhou X.; Hu Y.; Jin Z.; Liu J.; Fang J.; Synthesis and evaluation of novel ferrocenyl thiazole derivatives as anticancer agents. Synth React Inorg Met-Org Nano-Met Chem 2006,36(4),325-330","journal-title":"Synth React Inorg Met-Org Nano-Met Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejmech.2015.08.005","volume":"102","author":"Dawood K.M.","year":"2015","unstructured":"Dawood K.M.; Eldebss T.M.A.; El-Zahabi H.S.A.; Yousef M.H.; Synthesis and antiviral activity of some new bis-1,3-thiazole derivatives. Eur J Med Chem 2015,102,266-276","journal-title":"Eur J Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1573406415666190614101253","volume":"16","author":"Singh I.P.","year":"2020","unstructured":"Singh I.P.; Gupta S.; Kumar S.; Thiazole compounds as antiviral agents: An update. Med Chem 2020,16(1),4-23","journal-title":"Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1080\/10426507.2012.745542","volume":"188","author":"Shelke S.H.","year":"2013","unstructured":"Shelke S.H.; Mhaske P.C.; Hande P.; Bobade V.D.; Synthesis and antimicrobial activities of novel series of 1-((4-methyl-2-substituted thiazol-5-yl)methyleneam INO)-2-substituted isothiourea derivatives. Phosphorus Sulfur Silicon Relat Elem 2013,188(9),1262-1270","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/molecules22111827","volume":"22","author":"Oniga S.","year":"2017","unstructured":"Oniga S.; Araniciu C.; Palage M.; New 2-phenylthiazoles as potential sortase A inhibitors: Synthesis, biological evaluation and molecular docking. Molecules 2017,22(11),1827","journal-title":"Molecules"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1080\/10406638.2019.1708420","volume":"41","author":"El-Husseiny W.M.","year":"2021","unstructured":"El-Husseiny W.M.; Synthesis and biological evaluation of new 3-phenylthiazolidin-4-one and 3-phenylthiazole derivatives as antimicrobial agents. Polycycl Aromat Compd 2021,41(9),1988-2002","journal-title":"Polycycl Aromat Compd"},{"key":"ref=18","volume":"2013","author":"Mohamed S.","year":"2013","unstructured":"Mohamed S.; Synthesis and microbial activity of novel 3-methyl-2-  pyrazolin-5-one derivatives. J Chem Available from: 2013,2013","journal-title":"J Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5923\/j.ajoc.20120203.06","volume":"2","author":"Sharshira E.M.","year":"2012","unstructured":"Sharshira E.M.; Hamada N.M.M.; Synthesis, characterization and antimicrobial activities of some thiazole derivatives. Am J Org Chem 2012,2,69-73","journal-title":"Am J Org Chem"},{"key":"ref=20","first-page":"156","volume":"3","author":"Shreenivas M.T.","year":"2011","unstructured":"Shreenivas M.T.; Kumara Swamy B.E.; Srinivasa G.R.; Sherigara B.S.; Synthesis and antibacterial evaluation of some novel aminothiazole derivatives. Der Pharma Chem 2011,3(2),156-161","journal-title":"Der Pharma Chem"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.9734\/prri\/2013\/4306","volume":"3","author":"Khan I.","year":"2013","unstructured":"Khan I.; Ibrar A.; Waqas M.; White J.M.; Synthesis, X-ray crystallographic studies and antibacterial screening of 1-(5-(4-chlorophenyl) thiazol-2-yl) hydrazine hydrobromide 34. Phys Rev Res Int 2013,3,e17","journal-title":"Phys Rev Res Int"},{"key":"ref=22","first-page":"1","volume":"1","author":"Saravanan G.","year":"2010","unstructured":"Saravanan G.; Alagarsamy V.; Pavitra T.G.; Synthesis, characterization and anti-microbial activities of novel thiazole derivatives. Int J Pharma Bio Sci 2010,1,1-8","journal-title":"Int J Pharma Bio Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejmech.2018.03.083","volume":"151","author":"Lino C.I.","year":"2018","unstructured":"Lino C.I.; Gon&#xE7;alves de Souza I.; Borelli B.M.; Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives. Eur J Med Chem 2018,151,248-260","journal-title":"Eur J Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55379-1","volume":"9","author":"Mohammad H.","year":"2019","unstructured":"Mohammad H.; Eldesouky H.E.; Hazbun T.; Mayhoub A.S.; Seleem M.N.; Identification of a phenylthiazole small molecule with dual antifungal and antibiofilm activity against Candida albicans and Candida auris. Sci Rep 2019,9(1),1-12","journal-title":"Sci Rep"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ejmech.2013.04.005","volume":"65","author":"Helal M.H.M.","year":"2013","unstructured":"Helal M.H.M.; Salem M.A.; El-Gaby M.S.A.; Aljahdali M.; Synthesis and biological evaluation of some novel thiazole compounds as potential anti-inflammatory agents. Eur J Med Chem 2013,65,517-526","journal-title":"Eur J Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1080\/14756360802519558","volume":"24","author":"Sharma R.N.","year":"2009","unstructured":"Sharma R.N.; Xavier F.P.; Vasu K.K.; Chaturvedi S.C.; Pancholi S.S.; Synthesis of 4-benzyl-1,3-thiazole derivatives as potential anti-inflammatory agents: An analogue-based drug design approach. J Enzyme Inhib Med Chem 2009,24(3),890-897","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ejmech.2008.05.029","volume":"44","author":"Kouatly O.","year":"2009","unstructured":"Kouatly O.; Geronikaki A.; Kamoutsis C.; Hadjipavlou-Litina D.; Eleftheriou P.; Adamantane derivatives of thiazolyl-N-substituted amide, as possible non-steroidal anti-inflammatory agents. Eur J Med Chem 2009,44(3),1198-1204","journal-title":"Eur J Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jscs.2012.09.002","volume":"20","author":"Thore S.N.","year":"2016","unstructured":"Thore S.N.; Gupta S.V.; Baheti K.G.; Synthesis and pharmacological evaluation of 5-methyl-2-phenylthiazole-4-substituted heteroazoles as a potential anti-inflammatory and analgesic agents. J Saudi Chem Soc 2016,20,S46-S52","journal-title":"J Saudi Chem Soc"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0960-894X(99)00157-2","volume":"9","author":"Carter J.S.","year":"1999","unstructured":"Carter J.S.; Kramer S.; Talley J.J.; Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 1999,9(8),1171-1174","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"104608","DOI":"10.1016\/j.bioorg.2020.104608","volume":"107","author":"Kumar G.","year":"2021","unstructured":"Kumar G.; Singh N.P.; Synthesis, anti-inflammatory and analgesic evaluation of thiazole\/oxazole substituted benzothiazole derivatives. Bioorg Chem 2021,107,104608","journal-title":"Bioorg Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1021\/jm00362a014","volume":"26","author":"Hargrave K.D.","year":"1983","unstructured":"Hargrave K.D.; Hess F.K.; Oliver J.T.; N-(4-Substituted-thiazolyl)-oxamic acid derivatives, new series of potent, orally active antiallergy agents. J Med Chem 1983,26(8),1158-1163","journal-title":"J Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1021\/jm00092a006","volume":"35","author":"Patt W.C.","year":"1992","unstructured":"Patt W.C.; Hamilton H.W.; Taylor M.D.; Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem 1992,35(14),2562-2572","journal-title":"J Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2147\/DDDT.S106406","volume":"10","author":"Ma L.","year":"2016","unstructured":"Ma L.; Wang T.; Shi M.; Ye H.; Synthesis, activity, and docking study of phenylthiazole acids as potential agonists of PPAR&#x3B3;. Drug Des Devel Ther 2016,10,1807-1815","journal-title":"Drug Des Devel Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/1570163814666170915134018","volume":"15","author":"Khatik G.L.","year":"2018","unstructured":"Khatik G.L.; Datusalia A.K.; Ahsan W.; A retrospect study on thiazole derivatives as the potential antidiabetic agents in drug discovery and developments. Curr Drug Discov Technol 2018,15(3),163-177","journal-title":"Curr Drug Discov Technol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ja.2014.142","volume":"68","author":"Mohammad H.","year":"2015","unstructured":"Mohammad H.; Mayhoub A.S.; Cushman M.; Seleem M.N.; Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant Staphylococci. J Antibiot 2015,68(4),259-266","journal-title":"J Antibiot"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e0130385","DOI":"10.1371\/journal.pone.0130385","volume":"10","author":"Mohammad H.","year":"2015","unstructured":"Mohammad H.; Reddy P.V.N.; Monteleone D.; Antibacterial characterization of novel synthetic thiazole compounds against methicillin-resistant Staphylococcus pseudintermedius. PLoS One 2015,10(6),e0130385","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1021\/acs.jmedchem.6b00233","volume":"59","author":"Seleem M.A.","year":"2016","unstructured":"Seleem M.A.; Disouky A.M.; Mohammad H.; Second-generation phenylthiazole antibiotics with enhanced pharmacokinetic properties. J Med Chem 2016,59(10),4900-4912","journal-title":"J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ejmech.2017.10.048","volume":"143","author":"Hagras M.","year":"2018","unstructured":"Hagras M.; Hegazy Y.A.; Elkabbany A.H.; Biphenylthiazole antibiotics with an oxadiazole linker: An approach to improve physicochemical properties and oral bioavailability. Eur J Med Chem 2018,143,1448-1456","journal-title":"Eur J Med Chem"},{"key":"ref=39","year":"2017","unstructured":"Global Antimicrobial Resistance Surveillance System (GLASS) Report. Geneva World Health Organization 2017"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJMe058023","volume":"352","author":"Chambers H.F.","year":"2005","unstructured":"Chambers H.F.; Community-associated MRSA-resistance and virulence converge. N Engl J Med 2005,352(14),1485-1487","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-060614-034516","volume":"84","author":"Peacock S.J.","year":"2015","unstructured":"Peacock S.J.; Paterson G.K.; Mechanisms of Methicillin resistance in Staphylococcus aureus. Annu Rev Biochem 2015,84(1),577-601","journal-title":"Annu Rev Biochem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","volume":"1","author":"Hiramatsu K.","year":"2001","unstructured":"Hiramatsu K.; Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect Dis 2001,1(3),147-155","journal-title":"Lancet Infect Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.chembiol.2010.05.006","volume":"17","author":"Shekhar C.","year":"2010","unstructured":"Shekhar C.; Bacteria: Drug resistance spreads, but few new drugs emerge. Chem Biol 2010,17(5),413-414","journal-title":"Chem Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/jac\/dkg104","volume":"51","author":"Wilson P.","year":"2003","unstructured":"Wilson P.; Andrews J.A.; Charlesworth R.; Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003,51(1),186-188","journal-title":"J Antimicrob Chemother"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/AAC.05702-11","volume":"56","author":"Long K.S.","year":"2012","unstructured":"Long K.S.; Vester B.; Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 2012,56(2),603-612","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1093\/cid\/cit613","volume":"58","author":"Stryjewski M.E.","year":"2014","unstructured":"Stryjewski M.E.; Corey G.R.; Methicillin-resistant Staphylococcus aureus: An evolving pathogen. Clin Infect Dis 2014,58(Suppl. 1),S10-S19","journal-title":"Clin Infect Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-0711-12-22","volume":"12","author":"Bassetti M.","year":"2013","unstructured":"Bassetti M.; Merelli M.; Temperoni C.; Astilean A.; New antibiotics for bad bugs: Where are we? Ann Clin Microbiol Antimicrob 2013,12(1),22","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1086\/533452","volume":"197","author":"Rice L.B.","year":"2008","unstructured":"Rice L.B.; Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008,197(8),1079-1081","journal-title":"J Infect Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"Boucher H.W.","year":"2009","unstructured":"Boucher H.W.; Talbot G.H.; Bradley J.S.; Bad bugs, no drugs: No ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis 2009,48(1),1-12","journal-title":"Clin Infect Dis"},{"key":"ref=50","year":"2017","unstructured":"Antibacterial agents in clinical development: An analysis of the antibacterial clinical development pipeline, including tuberculosis Geneva World Heal Organ World Health OrganizationAvailable from: \nLicense: CC BY-NC-SA 3.0 IGO2017","journal-title":"Antibacterial agents in clinical development: An analysis of the antibacterial clinical development pipeline, including tuberculosis Geneva World Heal Organ"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.bmcl.2019.02.033","volume":"29","author":"Zhang T.Y.","year":"2019","unstructured":"Zhang T.Y.; Zheng C.J.; Wu J.; Sun L.P.; Piao H.R.; Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. Bioorg Med Chem Lett 2019,29(9),1079-1084","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejmech.2018.11.012","volume":"162","author":"Zha G.F.","year":"2019","unstructured":"Zha G.F.; Wang S.M.; Rakesh K.P.; Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections. Eur J Med Chem 2019,162,364-377","journal-title":"Eur J Med Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejmech.2019.02.058","volume":"168","author":"Yang Y.S.","year":"2019","unstructured":"Yang Y.S.; Lu X.; Zeng Q.X.; Synthesis and biological evaluation of 7-substituted cycloberberine derivatives as potent antibacterial agents against MRSA. Eur J Med Chem 2019,168,283-292","journal-title":"Eur J Med Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejmech.2019.02.004","volume":"167","author":"Tiz D.B.","year":"2019","unstructured":"Tiz D.B.; Skok &#x17D;.; Durcik M.; An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors. Eur J Med Chem 2019,167,269-290","journal-title":"Eur J Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.bmc.2019.02.024","volume":"27","author":"Cai S.","year":"2019","unstructured":"Cai S.; Yuan W.; Li Y.; Antibacterial activity of indolyl-quinolinium derivatives and study their mode of action. Bioorg Med Chem 2019,27(7),1274-1282","journal-title":"Bioorg Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejmech.2018.10.039","volume":"161","author":"Fang Z.","year":"2019","unstructured":"Fang Z.; Zheng S.; Chan K.F.; Design, synthesis and antibacterial evaluation of 2,4-disubstituted-6-thiophenyl-pyrimidines. Eur J Med Chem 2019,161,141-153","journal-title":"Eur J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejmech.2018.09.004","volume":"158","author":"Wu Y.","year":"2018","unstructured":"Wu Y.; Ding X.; Ding L.; Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents. Eur J Med Chem 2018,158,247-258","journal-title":"Eur J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1021\/acs.jmedchem.5b01984","volume":"59","author":"Wang Y.","year":"2016","unstructured":"Wang Y.; Chen F.; Di H.; Discovery of potent benzofuran-derived diapophytoene desaturase (CrtN) inhibitors with enhanced oral bioavailability for the treatment of methicillin- resistant Staphylococcus aureus (MRSA) infections. J Med Chem 2016,59(7),3215-3230","journal-title":"J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1021\/acs.jmedchem.6b00372","volume":"59","author":"Bouley R.","year":"2016","unstructured":"Bouley R.; Ding D.; Peng Z.; Structure-activity relationship for the 4(3H)-quinazolinone antibacterials. J Med Chem 2016,59(10),5011-5021","journal-title":"J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1039\/C5MD90029H","volume":"6","author":"Zhang L.","year":"2015","unstructured":"Zhang L.; Kumar K.V.; Rasheed S.; Zhang S.L.; Geng R.X.; Zhou C.H.; Correction: Design, synthesis, and antibacterial evaluation of novel azolylthioether quinolones as MRSA DNA intercalators. MedChemComm 2015,6(7),1405-1406","journal-title":"MedChemComm"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1021\/ja500053x","volume":"136","author":"O\u2019Daniel P.I.","year":"2014","unstructured":"O\u2019Daniel P.I.; Peng Z.; Pi H.; Discovery of a new class of non-&#x3B2;-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity. J Am Chem Soc 2014,136(9),3664-3672","journal-title":"J Am Chem Soc"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/jcp.17.3.243","volume":"17","author":"Jevons M.P.","year":"1964","unstructured":"Jevons M.P.; Parker M.T.; The evolution of new hospital strains of Staphylococcus aureus. J Clin Pathol 1964,17(3),243-250","journal-title":"J Clin Pathol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0966-842X(01)02175-8","volume":"9","author":"Hiramatsu K.","year":"2001","unstructured":"Hiramatsu K.; Cui L.; Kuroda M.; Ito T.; The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001,9(10),486-493","journal-title":"Trends Microbiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"Levine D.P.","year":"2006","unstructured":"Levine D.P.; Vancomycin: A history. Clin Infect Dis 2006,42(Suppl. 1),S5-S12","journal-title":"Clin Infect Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.cis.2013.06.009","volume":"205","author":"Schmidtchen A.","year":"2014","unstructured":"Schmidtchen A.; Pasupuleti M.; Malmsten M.; Effect of hydrophobic modifications in antimicrobial peptides. Adv Colloid Interface Sci 2014,205,265-274","journal-title":"Adv Colloid Interface Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"111830","DOI":"10.1016\/j.ejmech.2019.111830","volume":"185","author":"Hosny Y.","year":"2020","unstructured":"Hosny Y.; Abutaleb N.S.; Omara M.; Modifying the lipophilic part of phenylthiazole antibiotics to control their drug-likeness. Eur J Med Chem 2020,185,111830","journal-title":"Eur J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejmech.2016.11.042","volume":"126","author":"Yahia E.","year":"2017","unstructured":"Yahia E.; Mohammad H.; Abdelghany T.M.; Fayed E.; Seleem M.N.; Mayhoub A.S.; Phenylthiazole antibiotics: A metabolism-guided approach to overcome short duration of action. Eur J Med Chem 2017,126,604-613","journal-title":"Eur J Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ejmech.2017.08.039","volume":"139","author":"Eid I.","year":"2017","unstructured":"Eid I.; Elsebaei M.M.; Mohammad H.; Arylthiazole antibiotics targeting intracellular methicillin-resistant Staphylococcus aureus (MRSA) that interfere with bacterial cell wall synthesis. Eur J Med Chem 2017,139,665-673","journal-title":"Eur J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"112497","DOI":"10.1016\/j.ejmech.2020.112497","volume":"202","author":"Shahin I.G.","year":"2020","unstructured":"Shahin I.G.; Abutaleb N.S.; Alhashimi M.; Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections. Eur J Med Chem 2020,202,112497","journal-title":"Eur J Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1021\/acs.jmedchem.7b00392","volume":"60","author":"Hagras M.","year":"2017","unstructured":"Hagras M.; Mohammad H.; Mandour M.S.; Investigating the antibacterial activity of biphenylthiazoles against methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA). J Med Chem 2017,60(9),4074-4085","journal-title":"J Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ejmech.2018.04.049","volume":"152","author":"ElAwamy M.","year":"2018","unstructured":"ElAwamy M.; Mohammad H.; Hussien A.; Alkoxyphenylthiazoles with broad-spectrum activity against multidrug-resistant gram-positive bacterial pathogens. Eur J Med Chem 2018,152,318-328","journal-title":"Eur J Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1021\/acsinfecdis.8b00172","volume":"4","author":"Hagras M.","year":"2018","unstructured":"Hagras M.; Abutaleb N.S.; Ali A.O.; Naphthylthiazoles: Targeting multidrug-resistant and intracellular Staphylococcus aureus with biofilm disruption activity. ACS Infect Dis 2018,4(12),1679-1691","journal-title":"ACS Infect Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejmech.2018.03.044","volume":"151","author":"Kotb A.","year":"2018","unstructured":"Kotb A.; Abutaleb N.S.; Seleem M.A.; Phenylthiazoles with tert-Butyl side chain: Metabolically stable with anti-biofilm activity. Eur J Med Chem 2018,151,110-120","journal-title":"Eur J Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1021\/acsinfecdis.0c00137","volume":"6","author":"Hagras M.","year":"2020","unstructured":"Hagras M.; Abutaleb N.S.; Elhosseiny N.M.; Development of biphenylthiazoles exhibiting improved pharmacokinetics and potent activity against intracellular Staphylococcus aureus. ACS Infect Dis 2020,6(11),2887-2900","journal-title":"ACS Infect Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1039\/C8RA10525A","volume":"9","author":"Kotb A.","year":"2019","unstructured":"Kotb A.; Abutaleb N.S.; Hagras M.; tert-butylphenylthiazoles with an oxadiazole linker: A novel orally bioavailable class of antibiotics exhibiting antibiofilm activity. RSC Advances 2019,9(12),6770-6778","journal-title":"RSC Advances"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"103364","DOI":"10.1016\/j.bioorg.2019.103364","volume":"94","author":"Hannoun M.H.","year":"2020","unstructured":"Hannoun M.H.; Hagras M.; Kotb A.; El-Attar A.A.M.M.; Abulkhair H.S.; Synthesis and antibacterial evaluation of a novel library of 2-(thiazol-5-yl)-1,3,4-oxadiazole derivatives against methicillin-resistant Staphylococcus aureus (MRSA). Bioorg Chem 2020,94,103364","journal-title":"Bioorg Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejmech.2018.02.031","volume":"148","author":"Elsebaei M.M.","year":"2018","unstructured":"Elsebaei M.M.; Mohammad H.; Abouf M.; Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). Eur J Med Chem 2018,148,195-209","journal-title":"Eur J Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejmech.2019.04.063","volume":"175","author":"Elsebaei M.M.","year":"2019","unstructured":"Elsebaei M.M.; Mohammad H.; Samir A.; Lipophilic efficient phenylthiazoles with potent undecaprenyl pyrophosphatase inhibitory activity. Eur J Med Chem 2019,175,49-62","journal-title":"Eur J Med Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"127853","DOI":"10.1016\/j.bmcl.2021.127853","volume":"39","author":"Patel B.","year":"2021","unstructured":"Patel B.; Zunk M.; Grant G.; Rudrawar S.; Design, synthesis and bioactivity evaluation of novel pyrazole linked phenylthiazole derivatives in context of antibacterial activity. Bioorg Med Chem Lett 2021,39,127853","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221124112006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211193\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221124112006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:19:09Z","timestamp":1691713149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211193\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":79,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612829666221124112006","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}